Artemether

證據等級: L5

預測適應症: 10 個

Artemether: From Malaria Treatment to Acquired Angioedema

One-Sentence Summary

Artemether is a lipid-soluble artemisinin derivative, used as the backbone of artemisinin-based combination therapy (ACT) — most notably artemether-lumefantrine (Coartem) — and is globally established for treating uncomplicated and severe malaria caused by Plasmodium falciparum. The TxGNN model ranks Acquired Angioedema as its top novel predicted indication, with a score of 99.90%; however, no clinical trials and no published literature currently support this repurposing direction, placing it at the lowest evidence tier.

Quick Overview

Item	Content
Original Indication	Malaria (Plasmodium falciparum and other species)
Predicted New Indication	Acquired Angioedema
TxGNN Prediction Score	99.90%
Evidence Level	L5
Philippines Market Status	✗ Not Marketed
Number of Registrations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Detailed mechanism of action data was not available in this evidence pack. Based on known pharmacology, Artemether is a methyl ether derivative of dihydroartemisinin. Its core antimalarial activity stems from the endoperoxide bridge reacting with intraparasitic ferrous heme iron (Fe²⁺) to generate reactive oxygen species (ROS) and carbon-centered radicals, which selectively alkylate parasite proteins — including PfATP6 (a sarcoplasmic/endoplasmic reticulum Ca²⁺-ATPase) and histone proteins — disrupting membrane integrity and inducing oxidative death in asexual P. falciparum stages (trophozoites and schizonts). Beyond its antiparasitic activity, preclinical literature suggests that artemisinin-class compounds can also suppress NF-κB signaling and modulate complement activation.

Acquired angioedema is mechanistically driven by deficiency or dysfunction of C1-inhibitor (C1-INH), which leads to uncontrolled activation of the contact pathway, excessive kallikrein activity, and accumulation of bradykinin — ultimately causing episodic, self-limiting subcutaneous or submucosal edema. This pathway is pharmacologically distinct from any established target of artemether.

The proposed mechanistic hypothesis linking the two involves: artemether’s NF-κB inhibitory activity → reduced downstream pro-inflammatory mediators (IL-1β, TNF-α) → theoretical attenuation of vascular permeability; and a secondary hypothesis that artemisinin compounds may inhibit Factor XII or kallikrein-kinin pathway components. Both hypotheses remain entirely unvalidated experimentally. The high TxGNN score most likely reflects broad “inflammation” node connectivity within the knowledge graph rather than a disease-specific mechanistic link to acquired angioedema.

Clinical Trial Evidence

Currently no related clinical trials registered for Artemether in acquired angioedema.

Literature Evidence

Currently no related literature available for Artemether in acquired angioedema.

Philippines Market Information

Artemether is not currently registered with the FDA Philippines. No product authorizations are on record (total registrations: 0).

Safety Considerations

Please refer to the package insert for safety information.

Conclusion and Next Steps

Decision: Hold

Rationale: This prediction is supported by computational graph inference alone (L5); there is no clinical trial, no published literature, and no validated mechanistic pathway connecting artemether to acquired angioedema’s core pathophysiology (C1-INH deficiency → bradykinin excess). The drug is also not registered in the Philippines, adding an additional regulatory barrier.

To proceed, the following is needed:

In vitro mechanistic studies to determine whether artemether or its active metabolite dihydroartemisinin affects C1-INH activity, Factor XII activation, or kallikrein-kinin pathway components
A systematic literature review on artemisinin-class compounds and complement/bradykinin system interactions
Animal model validation (e.g., C1-INH-knockout or bradykinin-induced edema models) before any human studies
Full safety characterization relevant to the acquired angioedema population, including interactions with current standard-of-care agents (C1-INH concentrates, icatibant, lanadelumab)
Philippines FDA registration strategy if preclinical findings prove favorable

⚠️ Disclaimer: This report is for research reference only and does not constitute medical advice. Drug repurposing candidates require clinical validation before therapeutic application.

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.